Here are 1-3 brief analogies for Relmada Therapeutics (RLMD):

• A pre-commercial Eli Lilly, but exclusively focused on bringing one new depression treatment to market.

• An aspiring Gilead Sciences, aiming to transform depression treatment with one breakthrough drug.

• A specialized Moderna (before its vaccine success), developing a single, high-potential drug for depression.

• Esmethadone (REL-1017): A new chemical entity and N-methyl-D-aspartate receptor antagonist in Phase 3 clinical trials for the treatment of major depressive disorder in adults.

Relmada Therapeutics (RLMD) is a clinical-stage biotechnology company focused on developing therapies for central nervous system diseases. Its lead product candidate, Esmethadone (REL-1017), is currently in Phase 3 clinical trials for the treatment of major depressive disorder. As a clinical-stage company, Relmada Therapeutics is primarily engaged in research and development and has not yet commercialized any products. Therefore, the company does not currently have any major customers, as it is not generating revenue from product sales.

Sergio Traversa, Chief Executive Officer

Dr. Traversa is the co-founder and former CEO of Medeor Inc., a pharmaceutical company spun off from Cornell University. He possesses over 25 years of experience in the healthcare sector in both the United States and Europe, encompassing management roles in the pharmaceutical industry, as well as investing and strategic advisory capacities. His career includes positions as a financial analyst, portfolio manager, and strategic advisor at prominent U.S. investment firms focused on healthcare, such as Mehta and Isaly and Mehta partners, ING Barings, Merlin BioMed, and Rx Capital. Dr. Traversa was also a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he served as the Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson, and prior to that, was Marketing Manager of the Hospital Business Unit at Eli Lilly, where he contributed to the CNS team and participated in the launch of Prozac and the early development of Zyprexa and Cymbalta.

Maged Shenouda, Chief Financial Officer

Mr. Shenouda previously held the position of CFO and Executive Vice President of Corporate Development for AzurRx BioPharma, Inc. Before his tenure at AzurRx, he was the Senior Vice President and Head of Business Development and Licensing at Retrophin, Inc. Mr. Shenouda spent a significant portion of his career on Wall Street as an equity research analyst, holding senior-level positions at firms like UBS, JP Morgan, and Stifel Nicolaus, where he covered a diverse range of biotechnology companies. He served as a Director on Relmada's Board from 2015 before joining the executive management team as CFO in January 2020.

Raj S. Pruthi, Chief Medical Officer-Urology

Dr. Pruthi is an accomplished physician, surgeon, and clinical scientist with extensive experience in academic medicine and the industry. Prior to joining Relmada, he served as Chief Medical Officer at enGene Holdings Inc., where he led a global team in the development of a registrational therapeutic trial for bladder cancer. He also held the role of Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer) at Johnson and Johnson Innovative Medicine.

Charles Ence, Chief Accounting and Compliance Officer

Mr. Ence currently serves as Relmada's Chief Accounting and Compliance Officer. He previously held the position of Chief Financial Officer for Relmada before Maged Shenouda's appointment in January 2020, at which point he transitioned to his current role within the expanded financial team.

Paul Kelly, Chief Operating Officer

Mr. Kelly was appointed Chief Operating Officer effective January 1, 2025, to strengthen Relmada Therapeutics' leadership team.

The key risks to Relmada Therapeutics (RLMD) primarily stem from its position as a clinical-stage biotechnology company developing new product candidates.

1. Clinical Trial Failure and Regulatory Approval Risk for Lead Candidates: The most significant risk to Relmada Therapeutics is the potential for its current lead product candidates, particularly NDV-01 for non-muscle invasive bladder cancer (NMIBC), to fail in ongoing or future clinical trials or to not receive regulatory approval. The company previously terminated the development of its former lead candidate, Esmethadone (REL-1017), in July 2025 due to repeated failures in Phase 3 clinical trials for Major Depressive Disorder (MDD). Relmada has now shifted its primary focus to NDV-01, which is advancing into Phase 3 registrational programs by mid-2026. The success of NDV-01, and other pipeline candidates like sepranolone, is critical for the company's future, and there is no guarantee that these trials will demonstrate sufficient efficacy and safety, or that regulatory bodies will grant approval.
2. Financing and Liquidity Risk: As a clinical-stage company without revenue-generating products, Relmada Therapeutics is highly dependent on its ability to secure substantial additional financing to fund its extensive research and development activities, including expensive late-stage clinical trials. While the company has recently secured significant funding, such as a $160 million PIPE financing in March 2026 and a $100 million offering in November 2025, it previously faced substantial doubt about its ability to continue as a going concern in May 2025 due to projected insufficient liquidity. A continued need for capital could lead to further equity dilution for existing shareholders or an inability to complete product development if adequate funding cannot be secured on favorable terms.
3. Commercialization and Market Adoption Risk: Even if NDV-01 or sepranolone successfully complete clinical trials and receive regulatory approval, Relmada Therapeutics faces risks related to their successful commercialization and market adoption. This includes the challenge of competing with existing and future treatments, securing favorable pricing and reimbursement, and establishing effective sales and marketing capabilities. The market for NMIBC, while significant, has existing treatment options and requires the company to effectively differentiate its product to gain market share.

null

Addressable Market for Major Depressive Disorder (MDD) Treatment:

• The global Major Depressive Disorder market was estimated to be approximately USD 7.165 billion across the 7 Major Markets (7MM: United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) in 2023. This market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.6% during the forecast period of 2024–2034.
• Another estimate places the global Major Depressive Disorder market size at US$ 6.84 billion in 2024, with an expectation to reach US$ 14.57 billion by 2033, growing at a CAGR of 8.8% from 2025 to 2033.
• The Major Depressive Disorder market across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada) is projected to increase from $4.7 billion in 2019 to $9.6 billion in 2029, with a CAGR of 7.4%.
• The United States represents a significant portion of this market. In 2023, the U.S. market for Major Depressive Disorder was the largest among the 7MM, accounting for approximately USD 5.6 billion, and is expected to continue growing at a CAGR of 4.8% by 2034. The U.S. market alone comprised approximately 78% of the total 7MM market size in 2023.
• North America is expected to maintain a significant position in the global MDD treatment market due to high diagnosis rates, comprehensive insurance coverage for treatment, and substantial investment in new therapies.

Share Issuance

• Relmada Therapeutics announced an oversubscribed private placement expected to raise approximately $160.0 million in gross proceeds, closing around March 11, 2026. This financing involves selling 29,474,569 shares of common stock and pre-funded warrants for 4,210,527 shares.
• In November 2025, the company completed an underwritten offering of common stock and pre-funded warrants, which generated approximately $100 million in gross proceeds.
• Stockholders approved an amendment to the 2021 Equity Incentive Plan on May 23, 2025, increasing the number of shares available for issuance by 2,000,000, bringing the aggregate to 9,900,000 shares.

Inbound Investments

• An oversubscribed private placement, expected to close around March 11, 2026, secured approximately $160.0 million in gross proceeds from institutional investors including Venrock Healthcare Capital Partners, Commodore Capital, Janus Henderson Investors, RA Capital Management, OrbiMed, and Marshall Wace.
• During the fourth quarter of 2025, several institutional investors significantly increased their positions in Relmada Therapeutics, with Janus Henderson Group PLC adding 7,270,000 shares, Marshall Wace, LLP adding 2,917,609 shares, and OrbiMed Advisors LLC adding 2,610,600 shares to their portfolios.

Capital Expenditures

• Relmada Therapeutics invested $11K in capital expenditures during Q3 2025, an increase of 252.8% from the previous quarter, primarily funding long-term assets and infrastructure.
• The net proceeds from the $160.0 million private placement are intended for working capital and general corporate purposes, including advancing research and development of product candidates.
• Management anticipates an increase in spending with the initiation of NDV-01 and sepranolone clinical trials in 2026.